Industry
Biotechnology
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
August 12, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 6:49 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 1:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:11 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 9:15 am
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 3:32 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 3:58 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 10:39 am
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 4:16 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 11:03 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.